We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Dáil

Written answer

Medicinal Products

792. Deputy Paul Lawless asked the Minister for Health if she is aware of ongoing shortages of rapamune 1mg medication affecting transplant recipients; if she is aware of the case of a heart transplant patient who was forced to travel from Mayo to Dublin to secure an emergency supply after being unable to source the medication locally; and the urgent measures being taken to protect patients who depend on this life-sustaining medication. [78692/26]

Comment on this

The Health Products Regulatory Authority (HPRA) is the competent authority for the regulation of medicines in Ireland.

Sirolimus (Rapamune®) is an authorised medicinal product in Ireland. The Marketing Authorisation Holder, Pfizer, has confirmed that Rapamune is currently available for supply to Irish patients across all marketed presentations, including 1 mg tablets, and that no shortages are anticipated or ongoing.

Rapamune 1 mg remains authorised in Ireland and is listed as an authorised medicinal product on the HPRA Authorised Medicines database.

In relation to the specific case raised,  the Department has engaged with the HSE and the relevant transplant centre and understands that this appears to have been an isolated issue involving the patient and their community pharmacy, which has since been resolved. No other supply issues have been reported and no supplier shortage has been identified.

Comment on this